Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2019 to Jul 2024
UTEK Corporation (AMEX:UTK) (LSE-AIM:UTK), a specialty finance company
focused on technology transfer, and GammaCan International, Inc.
(OTCBB:GCAN), a developer of immunotherapies for the treatment of
melanoma, cancers and other diseases, are pleased to announce that they
have signed a strategic alliance agreement.
“We are enthusiastic about working with UTEK,
whose technology transfer model is unique in the industry. This alliance
may assist us in locating and acquiring technology and intellectual
properties to complement current research and development projects, as
well as expanding our core competencies,”
commented Patrick Schnegelsberg, Chief Executive Officer of GammaCan
International, Inc. “Accordingly, we believe
GammaCan’s pipeline related to Intravenous
IgG therapy technology could potentially broaden as a result of working
with UTEK.”
“UTEK looks forward to working with GammaCan,
Inc. to identify potential technology acquisition opportunities that fit
its strategic vision,” commented William
Porter, Chief Technology Transfer Officer of UTEK Corporation.
Through its strategic alliance agreements, UTEK assists companies in
enhancing their new product pipeline with the acquisition of proprietary
intellectual capital from universities and laboratory research centers.
Strategic alliance agreements are generally cancelable by either party
with thirty days advance written notice.
About GammaCan International, Inc.
GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IgG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IgG works by strengthening the
patient's immune system. Many experts currently view immunotherapy as a
future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IgG
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IgG and vitiligo-derived IgG (VitiGam).
For more information about GammaCan, please visit its website at www.GammaCan.com.
About UTEK Corporation
UTEK® is a specialty
finance company focused on technology transfer. UTEK’s
services enable companies to acquire innovative technologies from
universities and research laboratories worldwide. UTEK facilitates the
identification and acquisition of external technologies for clients in
exchange for their equity securities. This unique process is called U2B®.
In addition, UTEK offers companies the tools to search, analyze and
manage university intellectual properties. UTEK is a business
development company with operations in the United States, United Kingdom
and Israel. For more information about UTEK, please visit its website at www.utekcorp.com.
Forward-Looking Statements
Certain matters discussed in this press release are "forward-looking
statements." These forward-looking statements can generally be
identified as such because the context of the statement will include
words, such as UTEK or GammaCan International, Inc. "expects," "should,"
"believes," "anticipates" or words of similar import. Similarly,
statements that describe UTEK's or GammaCan International, Inc. future
plans, objectives or goals are also forward-looking statements. Such
forward-looking statements are subject to certain risks and
uncertainties, including the financial performance of UTEK or GammaCan
International, Inc., as appropriate, and the valuation of UTEK's
investment portfolio, which could cause actual results to differ
materially from those currently anticipated. Although UTEK and GammaCan
International, Inc. believe the expectations reflected in any
forward-looking statements are based on reasonable assumptions, they
cannot give any assurance that their expectations will be attained.
Shareholders, potential investors and other readers are urged to
consider these factors carefully in evaluating any forward-looking
statements. Certain factors could cause results and conditions to differ
materially from those projected in these forward-looking statements, and
some of these factors are discussed below. These factors are not
exhaustive. New factors, risks and uncertainties may emerge from time to
time that may affect the forward-looking statements made herein. These
forward-looking statements are only made as of the date of this press
release and both UTEK and GammaCan International, Inc. do not undertake
any obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances.
UTEK's operating results could fluctuate significantly due to a number
of factors. These factors include the small number of transactions that
are completed each quarter, the value of individual transactions, the
timing of the recognition and the magnitude of unrealized gains and
losses, UTEK's dependence on the performance of companies in its
portfolio, the possibility that advances in technology could render the
technologies it has transferred obsolete, the loss of technology
licenses by companies in its portfolio, the degree to which it
encounters competition in its markets, the volatility of the stock
market and the volatility of the valuations of the companies it has
invested in as it relates to its realized and unrealized gains and
losses, the concentration of investments in a small number of companies,
as well as other general economic conditions. As a result of these and
other factors, current results may not be indicative of UTEK's future
performance. For more information on UTEK and for a more complete
discussion of the risks pertaining to an investment in UTEK, please
refer to UTEK's filings with the Securities and Exchange Commission.
UTEK Corporation (AMEX:UTK) (LSE-AIM:UTK), a specialty finance
company focused on technology transfer, and GammaCan International,
Inc. (OTCBB:GCAN), a developer of immunotherapies for the treatment of
melanoma, cancers and other diseases, are pleased to announce that
they have signed a strategic alliance agreement.
"We are enthusiastic about working with UTEK, whose technology
transfer model is unique in the industry. This alliance may assist us
in locating and acquiring technology and intellectual properties to
complement current research and development projects, as well as
expanding our core competencies," commented Patrick Schnegelsberg,
Chief Executive Officer of GammaCan International, Inc. "Accordingly,
we believe GammaCan's pipeline related to Intravenous IgG therapy
technology could potentially broaden as a result of working with
UTEK."
"UTEK looks forward to working with GammaCan, Inc. to identify
potential technology acquisition opportunities that fit its strategic
vision," commented William Porter, Chief Technology Transfer Officer
of UTEK Corporation.
Through its strategic alliance agreements, UTEK assists companies
in enhancing their new product pipeline with the acquisition of
proprietary intellectual capital from universities and laboratory
research centers. Strategic alliance agreements are generally
cancelable by either party with thirty days advance written notice.
About GammaCan International, Inc.
GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IgG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IgG works by strengthening the
patient's immune system. Many experts currently view immunotherapy as
a future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IgG
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IgG and vitiligo-derived IgG (VitiGam).
For more information about GammaCan, please visit its website at
www.GammaCan.com.
About UTEK Corporation
UTEK(R) is a specialty finance company focused on technology
transfer. UTEK's services enable companies to acquire innovative
technologies from universities and research laboratories worldwide.
UTEK facilitates the identification and acquisition of external
technologies for clients in exchange for their equity securities. This
unique process is called U2B(R). In addition, UTEK offers companies
the tools to search, analyze and manage university intellectual
properties. UTEK is a business development company with operations in
the United States, United Kingdom and Israel. For more information
about UTEK, please visit its website at www.utekcorp.com.
Forward-Looking Statements
Certain matters discussed in this press release are
"forward-looking statements." These forward-looking statements can
generally be identified as such because the context of the statement
will include words, such as UTEK or GammaCan International, Inc.
"expects," "should," "believes," "anticipates" or words of similar
import. Similarly, statements that describe UTEK's or GammaCan
International, Inc. future plans, objectives or goals are also
forward-looking statements. Such forward-looking statements are
subject to certain risks and uncertainties, including the financial
performance of UTEK or GammaCan International, Inc., as appropriate,
and the valuation of UTEK's investment portfolio, which could cause
actual results to differ materially from those currently anticipated.
Although UTEK and GammaCan International, Inc. believe the
expectations reflected in any forward-looking statements are based on
reasonable assumptions, they cannot give any assurance that their
expectations will be attained. Shareholders, potential investors and
other readers are urged to consider these factors carefully in
evaluating any forward-looking statements. Certain factors could cause
results and conditions to differ materially from those projected in
these forward-looking statements, and some of these factors are
discussed below. These factors are not exhaustive. New factors, risks
and uncertainties may emerge from time to time that may affect the
forward-looking statements made herein. These forward-looking
statements are only made as of the date of this press release and both
UTEK and GammaCan International, Inc. do not undertake any obligation
to publicly update such forward-looking statements to reflect
subsequent events or circumstances.
UTEK's operating results could fluctuate significantly due to a
number of factors. These factors include the small number of
transactions that are completed each quarter, the value of individual
transactions, the timing of the recognition and the magnitude of
unrealized gains and losses, UTEK's dependence on the performance of
companies in its portfolio, the possibility that advances in
technology could render the technologies it has transferred obsolete,
the loss of technology licenses by companies in its portfolio, the
degree to which it encounters competition in its markets, the
volatility of the stock market and the volatility of the valuations of
the companies it has invested in as it relates to its realized and
unrealized gains and losses, the concentration of investments in a
small number of companies, as well as other general economic
conditions. As a result of these and other factors, current results
may not be indicative of UTEK's future performance. For more
information on UTEK and for a more complete discussion of the risks
pertaining to an investment in UTEK, please refer to UTEK's filings
with the Securities and Exchange Commission.